Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2019 Feb 23

PMID 30792714

Citations 16

Authors

Lotte Nijhuis

Janneke G C Peeters

Sebastiaan J Vastert

Jorg van Loosdregt

Affiliations

Soon will be listed here.

Abstract

Juvenile Idiopathic Arthritis (JIA) is characterized by a loss of immune tolerance. Here, the balance between the activity of effector T (Teff) cells and regulatory T (Treg) cells is disturbed resulting in chronic inflammation in the joints. Presently, therapeutic strategies are predominantly aimed at suppressing immune activation and pro-inflammatory effector mechanisms, ignoring the opportunity to also promote tolerance by boosting the regulatory side of the immune balance. Histone deacetylases (HDACs) can deacetylate both histone and non-histone proteins and have been demonstrated to modulate epigenetic regulation as well as cellular signaling in various cell types. Importantly, HDACs are potent regulators of both Teff cell and Treg cell function and can thus be regarded as attractive therapeutic targets in chronic inflammatory arthritis. HDAC inhibitors (HDACi) have proven therapeutic potential in the cancer field, and are presently being explored for their potential in the treatment of autoimmune diseases. Specific HDACi have already been demonstrated to reduce the secretion of pro-inflammatory cytokines by Teff cells, and promote Treg numbers and suppressive capacity and . In this review, we outline the role of the different classes of HDACs in both Teff cell and Treg cell function. Furthermore, we will review the effect of different HDACi on T cell tolerance and explore their potential as a therapeutic strategy for the treatment of oligoarticular and polyarticular JIA.

Citing Articles

Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes.

Jung S, Ben Nasr M, Bahmani B, Usuelli V, Zhao J, Sabiu G Adv Mater. 2023; 35(40):e2300812.

PMID: 37357903 PMC: 10629472. DOI: 10.1002/adma.202300812.

Effects of Deacetylase Inhibition on the Activation of the Antioxidant Response and Aerobic Metabolism in Cellular Models of Fanconi Anemia.

Bertola N, Regis S, Bruno S, Mazzarello A, Serra M, Lupia M Antioxidants (Basel). 2023; 12(5).

PMID: 37237966 PMC: 10215951. DOI: 10.3390/antiox12051100.

Identification of candidate genes and pathways associated with juvenile idiopathic arthritis by integrative transcriptome-wide association studies and mRNA expression profiles.

Feng R, Lu M, Yin C, Xu K, Liu L, Xu P Arthritis Res Ther. 2023; 25(1):19.

PMID: 36755318 PMC: 9906884. DOI: 10.1186/s13075-023-03003-z.

The emerging role of regulatory cell-based therapy in autoimmune disease.

Ghobadinezhad F, Ebrahimi N, Mozaffari F, Moradi N, Beiranvand S, Pournazari M Front Immunol. 2023; 13:1075813.

PMID: 36591309 PMC: 9795194. DOI: 10.3389/fimmu.2022.1075813.

Microtubules restrict F-actin polymerization to the immune synapse via GEF-H1 to maintain polarity in lymphocytes.

Pineau J, Pinon L, Mesdjian O, Fattaccioli J, Dumenil A, Pierobon P Elife. 2022; 11.

PMID: 36111670 PMC: 9592083. DOI: 10.7554/eLife.78330.

References

de Zoeten E, Wang L, Sai H, Dillmann W, Hancock W . Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 2009; 138(2):583-94. PMC: 3369426. DOI: 10.1053/j.gastro.2009.10.037. View

de Zoeten E, Wang L, Butler K, Beier U, Akimova T, Sai H . Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol. 2011; 31(10):2066-78. PMC: 3133361. DOI: 10.1128/MCB.05155-11. View

Kim M, Kwon H, Lee Y, Baek J, Jang J, Lee S . Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001; 7(4):437-43. DOI: 10.1038/86507. View

Nusinzon I, Horvath C . Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation. Mol Cell Biol. 2006; 26(8):3106-13. PMC: 1446935. DOI: 10.1128/MCB.26.8.3106-3113.2006. View

Spange S, Wagner T, Heinzel T, Kramer O . Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol. 2008; 41(1):185-98. DOI: 10.1016/j.biocel.2008.08.027. View

Nair A, Boersma L, Schiltz L, Chaudhry M, Muschel R, Chaudry A . Paradoxical effects of trichostatin A: inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. Cancer Lett. 2001; 166(1):55-64. DOI: 10.1016/s0304-3835(01)00418-9. View

Philips R, Chen M, McWilliams D, Belmonte P, Constans M, Shapiro V . HDAC3 Is Required for the Downregulation of RORγt during Thymocyte Positive Selection. J Immunol. 2016; 197(2):541-54. PMC: 4940140. DOI: 10.4049/jimmunol.1502529. View

Grausenburger R, Bilic I, Boucheron N, Zupkovitz G, El-Housseiny L, Tschismarov R . Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol. 2010; 185(6):3489-97. PMC: 3175530. DOI: 10.4049/jimmunol.0903610. View

Beier U, Wang L, Han R, Akimova T, Liu Y, Hancock W . Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms. Sci Signal. 2012; 5(229):ra45. PMC: 3603571. DOI: 10.1126/scisignal.2002873. View

10.

Dovey O, Foster C, Conte N, Edwards S, Edwards J, Singh R . Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice. Blood. 2013; 121(8):1335-44. PMC: 3836254. DOI: 10.1182/blood-2012-07-441949. View

11.

Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S . Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol. 2009; 36(8):1580-9. DOI: 10.3899/jrheum.081115. View

12.

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View

13.

Yan K, Cao Q, Reilly C, Young N, Garcia B, Mishra N . Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity. J Biol Chem. 2011; 286(33):28833-28843. PMC: 3190691. DOI: 10.1074/jbc.M111.233932. View

14.

Bennett C, Christie J, Ramsdell F, Brunkow M, Ferguson P, Whitesell L . The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27(1):20-1. DOI: 10.1038/83713. View

15.

Peeters J, Vervoort S, Tan S, Mijnheer G, de Roock S, Vastert S . Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression. Cell Rep. 2015; 12(12):1986-96. DOI: 10.1016/j.celrep.2015.08.046. View

16.

Angiolilli C, Kabala P, Grabiec A, Van Baarsen I, Ferguson B, Garcia S . Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes. Ann Rheum Dis. 2016; 76(1):277-285. PMC: 5264225. DOI: 10.1136/annrheumdis-2015-209064. View

17.

Lovell D . Update on treatment of arthritis in children: new treatments, new goals. Bull NYU Hosp Jt Dis. 2006; 64(1-2):72-6. View

18.

Wehrens E, Prakken B, van Wijk F . T cells out of control--impaired immune regulation in the inflamed joint. Nat Rev Rheumatol. 2013; 9(1):34-42. DOI: 10.1038/nrrheum.2012.149. View

19.

Ciarlo E, Heinonen T, Lugrin J, Acha-Orbea H, Le Roy D, Auwerx J . Sirtuin 3 deficiency does not alter host defenses against bacterial and fungal infections. Sci Rep. 2017; 7(1):3853. PMC: 5478639. DOI: 10.1038/s41598-017-04263-x. View

20.

Chianelli M, Parisella M, Visalli N, Mather S, DAlessandria C, Pozzilli P . Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy. Diabetes Metab Res Rev. 2007; 24(2):115-22. DOI: 10.1002/dmrr.767. View